Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Revenue (2022 - 2026)

Axsome Therapeutics' Revenue history spans 5 years, with the latest figure at $191.2 million for Q1 2026.

  • On a quarterly basis, Revenue rose 57.42% to $191.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $708.2 million, a 125.63% increase, with the full-year FY2025 number at $638.5 million, up 65.55% from a year prior.
  • Revenue hit $191.2 million in Q1 2026 for Axsome Therapeutics, down from $196.0 million in the prior quarter.
  • Over the last five years, Revenue for AXSM hit a ceiling of $196.0 million in Q4 2025 and a floor of $500000.0 in Q4 2024.
  • Historically, Revenue has averaged $88.6 million across 5 years, with a median of $81.1 million in 2024.
  • Biggest five-year swings in Revenue: crashed 99.3% in 2024 and later skyrocketed 39099.8% in 2025.
  • Tracing AXSM's Revenue over 5 years: stood at $24.4 million in 2022, then skyrocketed by 193.5% to $71.5 million in 2023, then crashed by 99.3% to $500000.0 in 2024, then skyrocketed by 39099.8% to $196.0 million in 2025, then dropped by 2.45% to $191.2 million in 2026.
  • Business Quant data shows Revenue for AXSM at $191.2 million in Q1 2026, $196.0 million in Q4 2025, and $171.0 million in Q3 2025.